Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Ibandronate, a potent nitrogen-containing bisphosphonate, can be administered with extended interval dosing. Patient preferences were assessed for once-monthly versus once-weekly bisphosphonate treatment using a previously developed, open-label, cross-over trial design. RESEARCH DESIGN AND METHODS: This was a 6-month, prospective, randomized, open-label, multi-center study with a two-period and two-sequence cross-over treatment design. After screening, eligible patients (postmenopausal women with osteoporosis) were randomized to once-monthly ibandronate 150 mg followed by once-weekly alendronate 70 mg for a total of 6 months (Sequence A) or once-weekly alendronate followed by once-monthly ibandronate for a total of 6 months (Sequence B). The primary objective was to evaluate patient-reported preference for either the once-monthly ibandronate regimen or the once-weekly alendronate regimen based on responses to a preference questionnaire. RESULTS: A total of 342 patients were enrolled into this study (Sequence A, 170; Sequence B, 172). In the primary analysis of patient preference, 71.4% of women selected once-monthly ibandronate and 28.6% of women selected once-weekly alendronate. Overall, 66.1% preferred the once-monthly ibandronate regimen to the once-weekly alendronate regimen (26.5%) and 7.4% of participants stated no preference for either regimen. The preference rate for once-monthly ibandronate was statistically significant (p < 0.0001). 'Ease of following a treatment regimen for a long time' was the most common reason given for patient preference for both the once-monthly ibandronate (61%, 169/276) and once-weekly alendronate (25%, 70/276) regimens. Additionally, 17% (47/276) of patients who preferred once-monthly ibandronate chose 'it is easier to tolerate side effects' as did 4.3% (12/276) of patients who preferred alendronate. Significantly more women found once-monthly ibandronate to be more convenient (p < 0.0001). CONCLUSIONS: Significantly more women with postmenopausal osteoporosis preferred once-monthly ibandronate therapy to once-weekly alendronate therapy, and found the once-monthly regimen to be more convenient. Ease of following a treatment regimen for a long time was the most common reason given for the patients' preferences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846 · cited 5×
“1896 Patient preference for once-monthly ibandronate over once-weekly alendronate © 2005 LIBRAPHARM LTD – Curr Med Res Opin 2005; 21(12) Introduction”
BackgroundInfluentialLiberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332201 · Cited by 2,288
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Cummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752
Treatment of postmenopausal osteoporosis
Delmas, P. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08827-x · Cited by 681
Hochberg, M. C. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1586 · Cited by 480
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
Caro, J. J., Ishak, K. J., Huybrechts, K. F., Raggio, G., & Naujoks, C. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1652-z · Cited by 468
Incorporating Patients' Preferences into Medical Decisions
Kassirer, J. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302611 · Cited by 415
Cramer, J. A., Amonkar, M. M., Hebborn, A., & Altman, R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x61875 · Cited by 390
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
DUNEAR-JACOB, J., ERLEN, J. A., SCHLENK, E. A., RYAN, C. M., SEREIKA, S. M., & DOSWELL, W. M. (2000) · Annual Review of Nursing Research · doi:10.1891/0739-6686.18.1.48 · Cited by 323
Hochberg, M. C., Ross, P. D., Black, D., Cummings, S. R., Genant, H. K., Nevitt, M. C., Barrett-Connor, E., Musliner, T., Thompson, D., & for the Fracture Intervention Trial Research Group (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199906)42:6<1246::aid-anr22>3.0.co;2-u · Cited by 287
(BONE), F. T. O. I. O. V. F. T. I. N. A. A. E., Delmas, P. D., Recker, R. R., Chesnut, C. H., Skag, A., Stakkestad, J. A., Emkey, R., Gilbride, J., Schimmer, R. C., & Christiansen, C. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1602-9 · Cited by 279
Self-citationRosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043801 · Cited by 256
Recker, R. R., Gallagher, R., & MacCosbe, P. E. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.7.856 · Cited by 250
Preferences for medical collaboration: patient–physician congruence and patient outcomes
Jahng, K. H., Martin, L. R., Golin, C. E., & DiMatteo, M. R. (2005) · Patient Education and Counseling · doi:10.1016/j.pec.2004.08.006 · Cited by 212
An exact test for comparing matched proportions in crossover designs
GART, J. J. (1969) · Biometrika · doi:10.1093/biomet/56.1.75 · Cited by 178
Simon, J. A., Michael Lewiecki, E., Smith, M. E., Petruschke, R. A., Wang, L., & Palmisano, J. J. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80085-6 · Cited by 170
Oral Daily Ibandronate Prevents Bone Loss in Early Postmenopausal Women Without Osteoporosis
Mcclung, M. R., Wasnich, R. D., Recker, R., Cauley, J. A., Chesnut, C. H., Ensrud, K. E., Burdeska, A., & Mills, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301202 · Cited by 125
The Comparison of Success Rates in Cross-Over Trials in the Presence of an Order Effect
Prescott, R. J. (1981) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.2307/2346652 · Cited by 116
Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes.
Wahl, C., Grégoire, J.-P., Teo, K., Beaulieu, M., Labelle, S., Leduc, B., Cochrane, B., Lapointe, L., & Montague, T. (2005) · Healthcare Quarterly · doi:10.12927/hcq..16941 · Cited by 108
Chesnut, C. H., Ettinger, M. P., Miller, P. D., Baylink, D. J., Emkey, R., Harris, S. T., Wasnich, R. D., Watts, N. B., Schimmer, R. C., & Recker, R. R. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x30752 · Cited by 98
Self-citationEpstein, S. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.3.379 · Cited by 74
New Effort to Develop Molecular Tools for Early Cancer Detection Under Way
Kuehn, B. M. (2005) · JAMA · doi:10.1001/jama.293.7.783 · Cited by 45
Israeli Alendronate OW Study Group, Weiss, M., Vered, I., Foldes, A. J., Cohen, Y. C., Shamir-Elron, Y., & Ish‐Shalom, S. (2005) · Aging Clinical and Experimental Research · doi:10.1007/bf03324587 · Cited by 26
Better Osteoporosis Management a Priority
Kuehn, B. M. (2005) · JAMA · doi:10.1001/jama.293.20.2453
Cited by
Siris, E. S., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., & Silverman, S. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.8.1013 · Cited by 704
Inoue, Y., Shimojo, N., Suzuki, S., Arima, T., Tomiita, M., Minagawa, M., & Kohno, Y. (2008) · Clinical Rheumatology · doi:10.1007/s10067-008-0864-6 · Cited by 34
Metadata
- Authors
- Emkey, R., Koltun, W., Beusterien, K., Seidman, L., Kivitz, A., Devas, V., & Masanauskaite, D.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2005-10-24
- Volume
- 21
- Issue
- 12
- Pages
- 1895-1903
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W1995634245
- Cited by
- 170
- References
- 29
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.